Community Healthcare Trust

CHCT · NYSE

$13.15+$0.37 (+2.90%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $12.78

CHCT analyst rating

HoldConsensus of 3 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy1
Hold2
Underperform0
Sell0

12-month price target · 7 analysts

Average $17.75 (+35.0% upside)

Low: $17.17
Now: $13.15
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

CHCT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Oct 12, 2026	Maintains	Neutral	$17.00 → $14.00	44%
Truist Securities	Oct 9, 2026	Maintains	Buy	$18.00 → $17.00	45%
Evercore ISI Group	Sep 21, 2026	Maintains	In-Line	$18.00 → $17.00	45%
Piper Sandler	Aug 6, 2026	Maintains	Neutral	$20.00 → $17.00	44%
Evercore ISI Group	Aug 6, 2026	Maintains	In-Line	$17.00 → $18.00	45%
Piper Sandler	Jul 21, 2026	Maintains	Neutral	$18.00 → $20.00	44%
Truist Securities	Jun 11, 2026	Maintains	Buy	$19.00 → $20.00	45%
Truist Securities	Mar 10, 2026	Maintains	Buy	$20.00 → $19.00	45%
Piper Sandler	Feb 19, 2026	Maintains	Neutral	$17.00 → $18.00	44%
Evercore ISI Group	Feb 19, 2026	Maintains	In-Line	$16.00 → $17.00	45%

The case for and against

Updated Oct 21, 2026

Bull case

Community Healthcare is attractive because its differentiated focus on small, non-urban healthcare properties reduces competition, limits new supply, and supports a steadier pipeline of acquisition opportunities through management’s deep operator relationships. Near-term catalysts include a 220 bps occupancy improvement target versus the 2Q26 level, the likely resolution of the Assurance transition, and about $70 million of asset sales by year-end, while the recent dividend cut should preserve cashflow for accretive investment. Despite a -9.8% YTD total return versus +6.8% for the NAREIT Equity REIT index, the shares offer a 9.6% annual dividend yield and appear undervalued at 9.0x 2026 FFO versus a historical average of 12.6x.

Bear case

Community Healthcare is facing a constrained growth and valuation backdrop because higher interest rates are raising financing costs, with a 50 bp increase on the $285 million 2Q26 credit facility balance estimated to add $0.05 per share of interest expense. That pressure is already visible in lower earnings expectations, as 2026 FFO is reduced to $1.93 per share and 2027 FFO to $1.96, both below consensus, while capital constraints and a higher cost of capital limit acquisition-driven expansion. Although management sees value in the portfolio and has about $70 million of potential dispositions, acquisition yields are lower than AFFO yield, tenant and re-leasing risks remain elevated, and leverage near the high-5x net debt/EBITDA range leaves little room for missteps.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.